120 studies found for:    thalidomide myeloma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
2 Recruiting Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide Celgene™
3 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
4 Unknown  Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone
5 Recruiting Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Clarithromycin;   Drug: Thalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
6 Recruiting Optimising Renal Outcome in Myeloma Renal Failure
Conditions: Multiple Myeloma;   Chronic Kidney Disease
Interventions: Drug: Bortezomib;   Drug: Thalidomide;   Drug: Bendamustine;   Drug: Dexamethasone
7 Not yet recruiting A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD);   Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab;   Drug: Daratumumab
8 Recruiting Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Single ASCT with Thalidomide maintenance
9 Not yet recruiting Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Thalidomide;   Drug: Dexamethasone
10 Unknown  Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalidomide;   Drug: idarubicin
11 Unknown  Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib,Pirarubicin,Dexamethasone;   Drug: Thalidomide,Pirarubicin,Dexamethasone
12 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
13 Recruiting Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
Condition: Myeloma
Interventions: Drug: Thalidomide;   Drug: Lenalidomide;   Behavioral: Questionnaires
14 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
15 Recruiting The Effects of Huang-Lian-Jie-Du-Tang(HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: HLJDT
16 Recruiting A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Velcade;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Thalidomide;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Montelukast
17 Unknown  PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Adriamycin;   Drug: Dexamethasone
18 Unknown  TCD Followed by autoSCT for Newly Diagnosed MM Patients
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide
19 Recruiting Study of MLN9708 Plus Oral Dexamethasone or Plus Oral Cyclophosphamide and Dexamethasone or Plus Bendamustine and Dexamethasone or Plus Oral Thalidomide and Dexamethasone Followed by Maintenance With MLN9708 in Newly Diagnosed Elderly Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bendamustine;   Drug: Thalidomide
20 Unknown  Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years